Company
Recordati
Recordati has 17 drugs tracked on RxWires: 5 post-market, 4 in Phase 3, 5 in Phase 2, 1 in Phase 1/2, 1 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Plenvu | Post-Market | Colorectal Cancer |
| Pasireotide | Post-Market | Cushing's Disease |
| Silodosin | Post-Market | Benign Prostatic Hyperplasia |
| Osilodrostat | Post-Market | Hypertension |
| Intervention/Treatment | Post-Market | Endogenous Cushing Syndrome |
| Mercaptamine | Phase 3 | Cystinosis |
| Methadone | Phase 3 | Pain Related to Cancer |
| Siltuximab | Phase 3 | Acute Respiratory Distress Syndrome |
| NX-1207 | Phase 3 | Lower Urinary Tract Symptoms |
| Pasireotide Diaspartate | Phase 2 | Post-Bariatric Hypoglycemia |
| Lercanidipine | Phase 2 | Essential Hypertension |
| Hemin | Phase 2 | Gastroparesis |
| LCI699 | Phase 2 | Cushing Syndrome |
| Udonitrectag | Phase 2 | Neurotrophic Keratitis |
| Rec 0/0438 1 mg or Rec 0/0438 2 mg | Phase 1/2 | Neurogenic Detrusor Overactivity |
| Pasireotide cartridge with reusable ServoPen | Phase 1 | Pharmacokinetics |
| Chlormethine | Not Applicable | Mycosis Fungoides |
Latest
No recent events.
Follow Recordati on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.